NasdaqCM:LXRXPharmaceuticals
Lexicon Pharmaceuticals (LXRX) Is Up 52.5% After Q1 Loss Narrows And Revenue Jumps - Has The Bull Case Changed?
Lexicon Pharmaceuticals, Inc. reported first-quarter 2026 results on May 7, with revenue rising to US$21.1 million from US$1.26 million a year earlier and net loss narrowing to US$1.04 million from US$25.3 million.
Alongside this sharp improvement in quarterly financials, Lexicon recently secured up to US$100 million in non-dilutive debt capacity, extending its funding runway for upcoming regulatory and commercial milestones.
With revenue sharply higher and net loss greatly reduced, we’ll...